Table 3 Patient characteristics of all registered patients (n=28)

From: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Characteristics

No. of patients (%)

Age

 Median

68

 Range

49–89

Performance status

 0

11 (39)

 1

13 (47)

 2

4 (14)

Sex

 Male

10 (36)

 Female

18 (64)

Histology

 Adenocarcinoma

27 (96)

 Squamous cell carcinoma

1 (4)

 Large cell carcinoma

0 (0)

 Adenosquamous carcinoma

0 (0)

 Other

0 (0)

Smoking status

 Never

19 (68)

 Current/former

9 (32)

Stage

 IIIAa

1 (3)

 IIIB

5 (18)

 IV

22 (79)

Prior cancer therapy

 Chemotherapy

 

No

17 (61)

One regimen (adjuvant)

4 (14)

One regimen (not adjuvant)

5 (18)

Two regimens

2 (7)

 Recurrence after surgery

11 (39)

 Radiation

1 (4)

  1. aUnresectable, no indication for thoracic radiation because of a large radiation field.
Back to article page